Cervical Cancer Chemotherapy

Overview

Cervical Cancer chemotherapy is the use of cytotoxic and related systemic agents to treat cancer of the cervix by killing or arresting the growth of malignant cells. It is employed in several settings: concurrently with radiotherapy as chemoradiation to enhance local control in locally advanced disease, as neoadjuvant treatment to shrink tumors before surgery, as adjuvant therapy to address residual or high-risk disease, and as palliative treatment for metastatic or recurrent cancer. Platinum-based regimens, particularly cisplatin, form the backbone of radiosensitizing and systemic therapy, often combined with other agents, and treatment is increasingly augmented by targeted and immunologic approaches. Mechanistically, chemotherapeutic drugs interfere with DNA replication, repair, and cell division, exploiting the proliferative activity of tumor cells, while radiosensitizers increase the effectiveness of concurrent radiation. The molecular biology of cervical tumors, including activation of survival and proliferation pathways such as PI3K/AKT/mTOR, informs the rationale for targeted agents and influences response and resistance. Because most Cervical Cancer is driven by persistent high-risk HPV infection, vaccination and screening reduce the number of patients presenting with advanced disease that requires systemic treatment. Treatment selection integrates stage, histology, prior therapy, and tolerance, balancing efficacy against toxicity. Research examines chemotherapeutic and combination regimens, integration with surgery and radiotherapy, molecular determinants of response, and outcomes across Cervical Cancer.

Research published in this journal

6 peer-reviewed articles, ranked by relevance. Each links to its DOI.

This page summarises published research for orientation; it is not medical or professional advice.

Related topics